NASDAQ$TWST

Twist Bioscience Corporation · Q3 2020 earnings

Q3 2020 earnings · · Investor relations

Briefing

Reported strong revenue growth driven by synthetic biology and next-generation sequencing, along with solid orders and a robust pipeline.

Twist Bioscience reported a strong third quarter with total revenues of $21.2 million, a 56% increase compared to the same period in 2019. The company's net loss was $28.2 million, or $0.67 per share. They ended the quarter with $311.8 million in cash and short-term investments.

  • Total revenue increased by 56% compared to Q3 2019, reaching $21.2 million.
  • Total orders for the quarter were $24.7 million, up from $18.1 million in Q3 2019.
  • The company shipped products to 1,377 customers, compared to 834 in the same period last year.
  • Ended the quarter with $311.8 million in cash, cash equivalents and short-term investments.

Headline financials

Total Revenue

$21.2M

Previous: $13.6M+55.9%
EPS (adj)

-$0.67

Previous: -$0.92+27.2%
Capital Expenditures

-$7.64M

Previous: -$10.9M+29.6%
Free Cash Flow

-$35.9M

Previous: -$38.8M+7.6%
Net Income

-$28.2M

Previous: -$27.9M-1.0%
Operating Income

-$28.2M

Previous: -$28.1M-0.3%
Gross Profit

$4.74M

Previous: $2.21M+114.6%
Cash & Equivalents

$208M

Previous: $68.2M+204.7%
Total Assets

$408M

Previous: $207M+97.4%

Revenue & EPS history

Twist Bioscience · Revenue · Quarterly

$21.2M

Q3 2020+55.9%vs Q3 2019
Beat estimate in 7 of 11 quarters(64%)
ActualEstimate

Revenue by segment

Twist Bioscience · $218M total across 2 segments · Q3 2023

  • NGS Applications
    $120M+23.7%
  • DNA Synthesis & Protein
    $98M+22.5%

Forward guidance

No specific forward guidance was provided in the earnings report.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2020

Historical avgQ3 2020

+0.1%

Avg return

Earnings day

-2.1%

Avg return

5 days after

+0.8%

Avg return

30 days after

47%

14 / 30 earnings

Positive

+29.7%

Q4 2023

Best reaction

-23.2%

Q1 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2026-7.3%-5.9%+19.6%
Q1 2026+13.8%-5.9%-10.2%
Q4 2025-10.0%-14.9%+3.4%
Q2 2025-8.5%-16.9%-20.8%
Q1 2025+0.7%-0.1%-19.7%
Q4 2024+12.0%+14.5%+20.9%
Q3 2024-14.6%-16.0%-18.5%
Q2 2024+28.9%+34.9%+31.1%
Q1 2024+9.5%+5.1%+16.9%
Q4 2023+29.7%+24.9%+81.5%
Q3 2023+14.9%+9.3%+14.0%
Q2 2023+3.6%+2.1%+26.0%
Q1 2023-23.2%-15.2%-37.1%
Q4 2022+0.8%+0.5%-0.6%
Q3 2022+20.8%+12.4%-17.2%
Q2 2022-9.9%-16.3%-12.6%
Q1 2022-1.0%+6.0%-21.0%
Q4 2021-12.6%-14.1%-22.4%
Q3 2021-9.1%-15.8%-7.6%
Q2 2021+6.2%-9.4%-12.4%
Q1 2021-16.8%-5.5%-38.1%
Q4 2020-9.9%-0.8%+44.3%
Q3 2020-7.2%-16.3%-4.8%
Q2 2020+5.1%+4.6%+0.7%
Q1 2020+21.3%+14.0%+31.4%
Q4 2019+4.6%+5.8%-15.5%
Q3 2019-11.2%-11.8%-13.9%
Q2 2019-9.9%-9.7%-3.9%
Q1 2019-9.2%-11.8%-6.9%
Q4 2018-9.2%-9.4%+18.6%
Q3 2018
Q2 2018
Q1 2017
Q4 2017

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro